Early Access — free while we kick the tires
EdgarHawk

Lippman Evan

EVP, Business Development

Officer

Latest: EVP, Business Development selling · May 2026

1 filing analyzed · 1 company · Latest 2026-05-18

Companies

Company Buys Sells Direction
TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA 0 4 Net selling

Activity

May 2026
Sell
41,658 shares
$1,482,367
Significance 3/10

Lippman (EVP, Business Development) sold 41,658 shares at $35.58 via scheduled 10b5-1 plan; post-sale holdings 44,191 shares.

Evan Lippman executed 2 separate sales totaling 41,658 shares for $1,482,366.60 at $35.58 per share on 2026-05-14, reducing his post-transaction holdings to 44,191 shares from 85,849 shares (a -48.5% reduction in position size). This transaction was pre-arranged under a 10b5-1 trading plan adopted on 2025-11-10, making it a scheduled, non-discretionary sale that cannot be interpreted as reflecting real-time market judgment or conviction signals. At the transaction price of $35.58, Lippman sold near TEVA's 52-week high of $37.34, though the current price of $34.05 reflects a subsequent -8.8% decline from that high. The sale is material in absolute dollar terms ($1.5M) and represents a substantial reduction of his equity position, but the pre-arranged nature constrains inference about signaling or forward-looking intent.

Related insiders

Create a free account

Build watchlists, get email alerts on the tickers you follow, and read the full AI analysis on every insider filing.

Sign up — free during early access